Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Single Dose Administration in Subjects With Systemic Lupus Erythematosus

NCT02443506 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02443506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02443506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Double-blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 623 Following Single Dose Administration in Subjects With Systemic Lupus Erythematosus
Lead sponsor
Amgen
Phase
Phase 1
Overall status
Completed
Start date
October 31, 2004
Completion date
June 30, 2007
Enrollment
56 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus